The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton
Open accessAbstract
The mammalian TOR (mTOR) pathway integrates nutrient- and growth factor-derived signals to regulate growth, the process whereby cells accumulate mass and increase in size. mTOR is a large protein kinase and the target of rapamycin, an immunosuppressant that also blocks vessel restenosis and has potential anticancer applications. mTOR interacts with the raptor and GbetaL proteins to form a complex that is the target of rapamycin. Here, we demonstrate that mTOR is also part of a distinct complex defined by the novel protein rictor (rapamycin-insensitive companion of mTOR). Rictor shares homology with the previously described pianissimo from D. discoidieum, STE20p from S. pombe, and AVO3p from S. cerevisiae. Interestingly, AVO3p is part of a rapamycin-insensitive TOR complex that does not contain the yeast homolog of raptor and signals to the actin cytoskeleton through PKC1. Consistent with this finding, the rictor-containing mTOR complex contains GbetaL but not raptor and it neither regulates the mTOR effector S6K1 nor is it bound by FKBP12-rapamycin. We find that the rictor-mTOR complex modulates the phosphorylation of Protein Kinase C alpha (PKCalpha) and the actin cytoskeleton, suggesting that this aspect of TOR signaling is conserved between yeast and mammals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It was initially shown that mTORC2 modulates cell morphology via PKCα signaling [43].”
From HEM1 Actin Immunodysregulatory Disorder: Genotypes, Phenotypes, and Future Directions (2022) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“Rapamycin is an acute inhibitor of mTORC1 but not mTORC2 28.”
From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886
Flagged first, then by citations
Research works printed but not linked: 20
- Kim, 2002, mTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery, Cell, 110, 163, 10.1016/S0092-8674(02)00808-5 · DOI
- Kim, 2003, Gβl, Mol. Cell, 11, 895, 10.1016/S1097-2765(03)00114-X · DOI
- Hara, 2002, Raptor, a binding partner of Target of Rapamycin (TOR), mediates TOR action, Cell, 110, 177, 10.1016/S0092-8674(02)00833-4 · DOI
- Chen, 1997, A novel cytosolic regulator, Pianissimo, is required for chemoattractant receptor and G protein-mediated activation of the 12 transmembrane domain adenylyl cyclase in Dictyostelium, Genes Dev., 11, 3218, 10.1101/gad.11.23.3218 · DOI
- Hilti, 1999, Gene ste20 controls amiloride sensitivity and fertility in Schizosaccharomyces pombe, Curr. Genet., 35, 585, 10.1007/s002940050456 · DOI
- Wedaman, 2003, Tor Kinases are in distinct membrane-associated protein complexes in Saccharomyces cerevisiae, Mol. Biol. Cell, 14, 1204, 10.1091/mbc.E02-09-0609 · DOI
- Hara, 1998, Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism, J. Biol. Chem., 273, 14484, 10.1074/jbc.273.23.14484 · DOI
- Lynch, 2000, Regulation of amino acid-sensitive TOR signaling by leucine analogues in adipocytes, J. Cell. Biochem., 77, 234, 10.1002/(SICI)1097-4644(20000501)77:2<234::AID-JCB7>3.0.CO;2-I · DOI
- Xu, 2001, Metabolic regulation by leucine of translation initiation through the mTOR-signaling pathway by pancreatic beta-cells, Diabetes, 50, 353, 10.2337/diabetes.50.2.353 · DOI
- Burnett, 1998, RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E–BP1, Proc. Natl. Acad. Sci. USA, 95, 1432, 10.1073/pnas.95.4.1432 · DOI
- Isotani, 1999, Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro, J. Biol. Chem., 274, 34493, 10.1074/jbc.274.48.34493 · DOI
- Kuo, 1992, Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase, Nature, 358, 70, 10.1038/358070a0 · DOI
- Chung, 1992, Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kD S6 protein kinases, Cell, 69, 1227, 10.1016/0092-8674(92)90643-Q · DOI
- Brunn, 1996, Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and Ly294002, EMBO J., 15, 5256, 10.1002/j.1460-2075.1996.tb00911.x · DOI
- Stewart, 2003, Lentivirus-delivered stable gene silencing by RNAi in primary cells, RNA, 9, 493, 10.1261/rna.2192803 · DOI
- Wang, 2001, Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase, EMBO J., 20, 4370, 10.1093/emboj/20.16.4370 · DOI
- Gysin, 1996, Replacement of Ser657 of protein kinase C-alpha by alanine leads to premature down regulation after phorbol-ester-induced translocation to the membrane, Eur. J. Biochem., 240, 747, 10.1111/j.1432-1033.1996.0747h.x · DOI
- Nakashima, 2002, Protein kinase C alpha (PKC alpha), J. Biochem. (Tokyo), 132, 669, 10.1093/oxfordjournals.jbchem.a003272 · DOI
- Schmidt, 1997, The yeast phosphatidylinositol kinase homolog TOR2 activates RHO1 and RHO2 via the exchange factor ROM2, Cell, 88, 531, 10.1016/S0092-8674(00)81893-0 · DOI
- Turner, 2000, Paxillin and focal adhesion signalling, Nat. Cell Biol., 2, E231, 10.1038/35046659 · DOI
Cited by
Sorted by citations
Items 101–113 of 113
Lee, H.-K., Kwon, B., Lemere, C. A., de la Monte, S., Itamura, K., Ha, A. Y., & Querfurth, H. W. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161029 · Cited by 57
Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer
Rieder, S., W. Michalski, C., Friess, H., & Kleeff, >. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011795677454 · Cited by 50
ER Stress Induces Anabolic Resistance in Muscle Cells through PKB-Induced Blockade of mTORC1
Deldicque, L., Bertrand, L., Patton, A., Francaux, M., & Baar, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020993 · Cited by 50
Potentiation of insulin-stimulated glucose transport by the AMP-activated protein kinase
Ju, J.-S., Gitcho, M. A., Casmaer, C. A., Patil, P. B., Han, D.-G., Spencer, S. A., & Fisher, J. S. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00269.2006 · Cited by 47
Kong, M., Bui, T. V., Ditsworth, D., Gruber, J. J., Goncharov, D., Krymskaya, V. P., Lindsten, T., & Thompson, C. B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703159200 · Cited by 43
Zhu, C., Dixon, K. O., Newcomer, K., Gu, G., Xiao, S., Zaghouani, S., Schramm, M. A., Wang, C., Zhang, H., Goto, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd2710 · Cited by 40
Electroconvulsive seizures stimulate the vegf pathway via mTORC1
Elfving, B., & Wegener, G. (2012) · Synapse · doi:10.1002/syn.21518 · Cited by 40
Kroczynska, B., Rafidi, R. L., Majchrzak-Kita, B., Kosciuczuk, E. M., Blyth, G. T., Jemielity, J., Warminska, Z., Saleiro, D., Mehrotra, S., Arslan, A. D., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664995 · Cited by 29
Transcription factors and cognate signalling cascades in the regulation of autophagy
Chandra, V., Bhagyaraj, E., Parkesh, R., & Gupta, P. (2016) · Biological Reviews · doi:10.1111/brv.12177 · Cited by 26
HEM1 Actin Immunodysregulatory Disorder: Genotypes, Phenotypes, and Future Directions
Cook, S., Lenardo, M. J., & Freeman, A. F. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01327-0 · Cited by 24
mTORC2 deficiency alters the metabolic profile of conventional dendritic cells
Watson, A. R., Dai, H., Zheng, Y., Nakano, R., Giannou, A. D., Menk, A. V., Stolz, D. B., Delgoffe, G. M., & Thomson, A. W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01451 · Cited by 15
Characterization of mTOR Activity and Metabolic Profile in Pediatric Rhabdomyosarcoma
Felkai, L., Krencz, I., Kiss, D. J., Nagy, N., Petővári, G., Dankó, T., Micsík, T., Khoor, A., Tornóczky, T., Sápi, Z., et al. (2020) · Cancers · doi:10.3390/cancers12071947 · Cited by 13
Kou, P., Wei, S., & Xiong, F. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666180330094434 · Cited by 6
Metadata
- Authors
- Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M.
- Affiliations
- Whitehead Institute for Biomedical Research (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Sabatini, David M
- Venue
- Current Biology
- Publisher
- Elsevier BV
- Published
- 2004-07
- Volume
- 14
- Issue
- 14
- Pages
- 1296-1302
- ISSN
- 0960-9822 (ISSN-L)
- OpenAlex
- W2065887259
- Cited by
- 2,665
- References
- 1
- Citations by year
- 2026: 43 · 2025: 60 · 2024: 74 · 2023: 103 · 2022: 103 · 2021: 134 · 2020: 120 · 2019: 124 · 2018: 137 · 2017: 121 · 2016: 147 · 2015: 170 · 2014: 160 · 2013: 157 · 2012: 167
- FWCI
- 25.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Current Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- National Institute of Allergy and Infectious Diseases (R01AI047389)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Keywords
- Rictor, mTOR, TOR signaling, raptors, actin cytoskeleton, protein kinase C alpha, S6K1
- MeSH terms
- Regulatory-Associated Protein of mTOR, Rapamycin-Insensitive Companion of mTOR Protein, Actins, Amino Acid Sequence, Animals, Carrier Proteins, Cytoskeleton, Drosophila, Electrophoresis, Polyacrylamide Gel, Fluorescent Antibody Technique, HeLa Cells, Humans, Molecular Sequence Data, Phosphorylation, Precipitin Tests, Protein Kinase C, Protein Kinases, Proteins, Transfection, Immunoblotting, Sequence Alignment, Conserved Sequence, Sequence Analysis, DNA, DNA Primers, Sirolimus, RNA Interference, RNA, Small Interfering, Gene Components, Adaptor Proteins, Signal Transducing, Protein Kinase C-alpha, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review